Skip to main content

Table 3 Biomarker levels in the control group (conventional treatment) and in the intervention group (duration of antibiotic treatment based on IDSA / ATS), in the per-protocol analysis

From: Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia

 

Control

n = 61

Intervention

n = 75

p value

ProADM day 1

1.01 (0.78, 1.32)

0.91 (0.68, 1.25)

0.41

ProADM day 5

0.81 (0.57, 1.01)

0.81 (0.54, 1.19)

0.59

ProADM day 30

0.70 (0.49, 1.01)

0.68 (0.49, 0.93)

0.93

ProADM difference from day 5 to day 30

−0.07 (−0.23, 0.01)

−0.09 (−0.15, 0.03)

0.65

PCR day 1

240.20 (86.80, 301.30)

159.75 (87.75, 302.60)

0.47

PCR day 5

47.50 (25.10, 88.50)

37.10 (15.70, 79.30)

0.20

PCR day 30

2.55 (1.60, 7.80)

2.50 (1.30, 5.40)

0.48

PCR difference from day 5 to day 30

−42.30 (−86.70, −21.90)

−32.45 (−73.35, −14.50)

0.17

PCT day 1

0.67 (0.18, 3.34)

0.49 (0.15, 1.68)

0.67

PCT day 5

0.19 (0.09, 0.50)

0.17 (0.06, 0.75)

0.87

PCT day 30

0.04 (0.02, 0.06)

0.04 (0.03, 0.06)

0.54

PCT difference from day 5 to day 30

−0.12 (−0.40, −0.04)

−0.18 (− 0.69, − 0.03)

0.49

  1. Data are presented as median (IQR)
  2. IQR interquartile range